Qube Research & Technologies LTD Galectin Therapeutics Inc Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
A detailed history of Qube Research & Technologies LTD transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Qube Research & Technologies LTD holds 12,130 shares of GALT stock, worth $17,831. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,130Holding current value
$17,831% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding GALT
# of Institutions
112Shares Held
9.93MCall Options Held
3.78MPut Options Held
5.27M-
Vanguard Group Inc Valley Forge, PA2.14MShares$3.14 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.3 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.18MShares$1.74 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA871KShares$1.28 Million0.0% of portfolio
-
Wealthspire Advisors, LLC New York, NY398KShares$585,6090.0% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $87.4M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...